News & Press
- The patent covers the composition of RHAMM-Binding peptides as well as the use of peptides for diagnosing, and determining the prognosis for, cancer patients. The issuance of this patent is a significant milestone for Novare, which has an exclusive license to the patented technology.
Boston (July 30, 2015) – Novare Pharmaceuticals today announced that the U.S. Patent and Trademark Office issued patent #9,090,659, with claims covering the composition-of-matter and use of RHAMM-binding peptides with a wide range of potential therapeutic uses. The patent also has claims for the diagnosis and prognosis of cancer, and for prescribing a course of treatment for the diagnosed cancer.
Novare is developing therapeutic products that modulate the Receptor for Hyaluronan-Mediated Motility (RHAMM), a cellular protein that helps to regulate cell movement and stem cell differentiation. Novare’s RHAMM-based therapeutic products aim to safely and selectively stimulate cell differentiation as well as reduce destructive inflammation and scarring. Potential applications include the treatment of osteoarthritis, lung fibrosis, and several types of cancers such as lung, breast, prostate, and brain, as well as the prevention or reduction of tissue scarring.
The patent was issued to Lawson Health Research Institute, and names Drs. Leonard G. Luyt, Eva A. Turley and Mr. Kenneth V. Esguerra as the inventors. Novare, which has an exclusive, worldwide license to the patented technology, operates a research incubator within the London Regional Cancer Program under the direction of Drs. Turley and Luyt. Lawson is the research institution of London Health Sciences Centre and St. Joseph’s Health Care London located in Ontario, Canada.
”We are pleased to have reached this significant milestone as it allows us to move forward with pharmaceutical compositions for the treatment of several major diseases, including cancer,” said Dr. Turley, who also serves as Chief Scientist for Novare.
The patent also includes imaging methods to detect pathogenic cells, methods that can be applied to prognosis, and covers the prescription of a course of treatment based on an individual patient’s diagnosis and prognosis.
“The issuance of this patent is a major step forward for our research,” said Mike Delmage, Chief Executive Officer of Novare. “This new patent supports the therapeutic use of our RHAMM-binding peptides in progressive disease. It also provides Novare with a complete package for diagnosis, prognosis, and therapeutic treatment, all based on RHAMM binding. The work we are doing around positioning the RHAMM-binding peptides that can control inflammatory disease and cancerous tumors is a key differentiator for us.”
For more information about Novare’s research, see www.novarepharma.com. The company is a subsidiary of Boston-based Allied Minds (LSE: ALM).
ArcPoint Strategic Communications
Novare Pharmaceuticals was excited to be a silver sponsor of the 10th International Biennial meeting of the International Society of Hyaluronan Sciences held in Florence, Italy. The conference brought together industry professionals and scientists around topics in Hyaluronan research, including metabolism and physiology, differentiation and ageing, regenerative medicine, cardiovascular disease, cancer and other topics.
Posters and presentations given by Novare’s collaborators, including Drs. Connie Tolg (a colleague of Dr. Eva Turley at London Health Sciences Centre), Rashmin Savani (UT Southwestern Medical Center) and Mary Cowman (NYU) were well-received. Novare Pharmaceuticals generated a significant amount of interest, particularly since it was new to this venue. Dr. Ken Narducy, Chief Operating Officer of Novare, also attended the meeting and fielded inquiries from meeting participants and sponsors.
For more information on the conference program, visit https://www.ishas.org/2015-ha-conference.
Novare Pharmaceuticals is excited to be the recipient of the 2015 Lawson Industry Partner of the Year Award. Announced in May, 2015 at the annual Lawson Impact Awards ceremony, the distinction celebrates Lawson’s private sector partners for their efforts in promoting common goals for the advancement of global healthcare initiatives and providing critical support for life science research.
Lawson recognizes that Novare’s business acumen, including expertise in drug development, regulatory approval, quality assurance, financing and marketing is essential to ensure that the research of Drs. Eva Turley and Leonard Luyt ultimately benefits patients. The Lawson and Novare partnership, formally announced here serves as an inspiring and much-needed model for the development of early-stage technologies from academic health research organizations.
View a video highlighting Novare as the Lawson Industry Partner of the Year:
For more information on Lawson Health Research Institute, see their website at www.lawsonresearch.com.